Novo Nordisk
2012-04-06T18:50:24Z
2012-04-06T18:50:24Z
Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia®
Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia® (sitagliptin).
Further information:
| Media: | Investors: |
| Mike Rulis | Klaus Bülow Davidsen |
| Tel: (+45) 3079 3573 | Tel: (+45) 4442 3176 |
| mike@novonordisk.com | klda@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ambre Morley | Jannick Lindegaard |
| Tel: (+1) 609 216-5240 | Tel: (+1) 609 786 4575 |
| abmo@novonordisk.com | jlis@novonordisk.com |
Company Announcement no 22 / 2012